---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010108"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:50:43.347695+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023

## Summary
- Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.
- No hypoglycemia reported; 98% of adverse events mild/moderate; one SAE (gallstone obstruction) in a subject with history of cholelithiasis.
- VK2735 half-life ~170-250 hours; plans to evaluate higher doses with longer titration in Phase 2.
- Phase 2 trial in obesity expected to initiate in mid-2023.

## SEC filing metadata
- accession: 0000950170-23-010108
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/0000950170-23-010108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/vktx-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010108
- JSON: https://secwatch.observer/filing/0000950170-23-010108.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.